Although the efficacy of broad spectrum HDACi in GBM may be limited by the potential for reactivation of the DNA repair enzyme MGMT [56], recent studies have indicated that selective HDACi may improve the therapeutic window [57]. The gene discussed is MGMT; the disease is glioblastoma.